Jacques Amar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2217266/publications.pdf Version: 2024-02-01



IACOUES AMAD

#	Article	IF	CITATIONS
1	Metabolic Endotoxemia Initiates Obesity and Insulin Resistance. Diabetes, 2007, 56, 1761-1772.	0.6	4,964
2	Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Molecular Medicine, 2011, 3, 559-572.	6.9	694
3	Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut, 2012, 61, 543-553.	12.1	511
4	Energy intake is associated with endotoxemia in apparently healthy men. American Journal of Clinical Nutrition, 2008, 87, 1219-1223.	4.7	498
5	Comprehensive description of blood microbiome from healthy donors assessed by 16 <scp>S</scp> targeted metagenomic sequencing. Transfusion, 2016, 56, 1138-1147.	1.6	355
6	Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia, 2011, 54, 3055-3061.	6.3	283
7	The Gut Microbiota Regulates Intestinal CD4ÂT Cells Expressing RORγt and Controls Metabolic Disease. Cell Metabolism, 2015, 22, 100-112.	16.2	248
8	Arterial stiffness and cardiovascular risk factors in a population-based study. Journal of Hypertension, 2001, 19, 381-387.	0.5	242
9	Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. Hepatology, 2016, 64, 2015-2027.	7.3	230
10	Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney International, 2000, 57, 2485-2491.	5.2	211
11	Blood Microbiota Dysbiosis Is Associated with the Onset of Cardiovascular Events in a Large General Population: The D.E.S.I.R. Study. PLoS ONE, 2013, 8, e54461.	2.5	201
12	Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetologica, 2011, 48, 257-273.	2.5	199
13	Defective <scp>NOD</scp> 2 peptidoglycan sensing promotes dietâ€induced inflammation, dysbiosis, and insulin resistance. EMBO Molecular Medicine, 2015, 7, 259-274.	6.9	160
14	The Characterization of Novel Tissue Microbiota Using an Optimized 16S Metagenomic Sequencing Pipeline. PLoS ONE, 2015, 10, e0142334.	2.5	155
15	Metagenome and metabolism: the tissue microbiota hypothesis. Diabetes, Obesity and Metabolism, 2013, 15, 61-70.	4.4	112
16	Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. Journal of Hypertension, 2006, 24, 1083-1088.	0.5	64
17	Hypertension in high-risk patients: beware of the underuse of effective combination therapy (results) Tj ETQq1	0.784314	rgBT /Overld
18	Soluble CD14 and aortic stiffness in a population-based study. Journal of Hypertension, 2003, 21, 1869-1877.	0.5	54

JACQUES AMAR

#	Article	IF	CITATIONS
19	Why is hypertension so frequently uncontrolled in secondary prevention?. Journal of Hypertension, 2003, 21, 1199-1205.	0.5	53
20	The gut microbiota ecology: a new opportunity for the treatment of metabolic diseases ?. Frontiers in Bioscience - Landmark, 2009, 14, 5107.	3.0	52
21	Triggering the adaptive immune system with commensal gut bacteria protects against insulin resistance and dysglycemia. Molecular Metabolism, 2016, 5, 392-403.	6.5	50
22	Relationship between C reactive protein and pulse pressure is not mediated by atherosclerosis or aortic stiffness. Journal of Hypertension, 2004, 22, 349-355.	0.5	34
23	C-Reactive Protein Elevation Predicts Pulse Pressure Reduction in Hypertensive Subjects. Hypertension, 2005, 46, 151-155.	2.7	33
24	Hypertension and pregnancy: expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology. Fundamental and Clinical Pharmacology, 2017, 31, 83-103.	1.9	30
25	Comparison of Hypertension Management After Stroke and Myocardial Infarction. Stroke, 2004, 35, 1579-1583.	2.0	28
26	Blood Microbiota Modification After Myocardial Infarction Depends Upon Lowâ€Density Lipoprotein Cholesterol Levels. Journal of the American Heart Association, 2019, 8, e011797.	3.7	27
27	CD14 C(â^260)T gene polymorphism, circulating soluble CD14 levels and arteriosclerosis. Journal of Hypertension, 2004, 22, 1523-1528.	0.5	24
28	Six-item self-administered questionnaires in the waiting room: an aid to explain uncontrolled hypertension in high-risk patients seen in general practice. Journal of the American Society of Hypertension, 2009, 3, 221-227.	2.3	18
29	Prediction of persistence of combined evidence-based cardiovascular medications in patients with acute coronary syndrome after hospital discharge using neural networks. Medical and Biological Engineering and Computing, 2011, 49, 947-955.	2.8	17
30	Persistence of combination of evidence-based medical therapy in patients with acute coronary syndromes. Archives of Cardiovascular Diseases, 2008, 101, 301-306.	1.6	16
31	Poor blood pressure control in general practice: In search of explanations. Archives of Cardiovascular Diseases, 2009, 102, 477-483.	1.6	15
32	Cardiovascular Risk Factors, Atherosclerosis and Pulse Pressure. , 2006, 44, 212-222.		14
33	Arteries, inflammation and insulin resistance. Journal of Hypertension, 2006, 24, S18-S20.	0.5	11
34	Identification by highly sensitive 16S metagenomic sequencing of an unusual case of polymicrobial bacteremia. Journal of Infection, 2017, 75, 278-280.	3.3	11
35	Microbiota–Host Crosstalk: A Bridge Between Cardiovascular Risk Factors, Diet, and Cardiovascular Disease. American Journal of Hypertension, 2018, 31, 941-944.	2.0	10
36	Patients with resistant hypertension. Journal of Hypertension, 2007, 25, S3-S6.	0.5	9

JACQUES AMAR

#	Article	IF	CITATIONS
37	Gut Microbiota and Metabolic Diseases: From Pathogenesis to Therapeutic Perspective. Molecular and Integrative Toxicology, 2015, , 199-234.	0.5	7
38	Antibiotics or prodiabetics?. Nature Reviews Endocrinology, 2015, 11, 385-386.	9.6	5
39	Interactions between hypertension and inflammatory tone and the effect on blood pressure and outcomes in patients with COVIDâ€19. Journal of Clinical Hypertension, 2021, 23, 238-244.	2.0	5
40	Commentary. Evidence-based Cardiovascular Medicine, 2004, 8, 32-33.	0.0	0
41	Baseline and target blood pressure for the prevention of recurrent stroke. Journal of Hypertension, 2006, 24, 2473.	0.5	0